Osimertinib, an irreversible third-generation EGFR TKI, is highly effective in both untreated and previously treated patients with EGFR-mutant NSCLC, according to several encouraging international clinical trials (13–15, 28). Here, EGFR is linked to non-small cell lung carcinoma.